Literature DB >> 23812257

First-in-class insomnia drug on the brink of approval nod.

Randy Osborne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23812257     DOI： 10.1038/nrd4067

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  3 in total

1.  Suvorexant, a dual orexin receptor antagonist for the management of insomnia.

Authors:  Tiffany Bennett; David Bray; Michael W Neville
Journal:  P T       Date:  2014-04

Review 2.  Orexin/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: Potential for therapy.

Authors:  Cliff H Summers; Jazmine D W Yaeger; Clarissa D Staton; David H Arendt; Tangi R Summers
Journal:  Brain Res       Date:  2018-12-24       Impact factor: 3.252

3.  Insomnia and hypertension: A misty landscape.

Authors:  Konstantinos Stavropoulos; Konstantinos P Imprialos; Michael Doumas; Asterios Karagiannis; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-03-15       Impact factor: 3.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.